Published in Infect Immun on October 01, 1983
Lung infections associated with cystic fibrosis. Clin Microbiol Rev (2002) 9.20
Cystic fibrosis: yesterday, today and tomorrow. J R Soc Med (1991) 1.88
Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiol Infect (1989) 1.69
Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax (1990) 1.67
Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol (1987) 1.49
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child (1986) 1.49
Microbiology of cystic fibrosis lung infections: themes and issues. J R Soc Med (1993) 1.46
Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa. J Clin Microbiol (1995) 1.40
Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci U S A (2003) 1.40
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid Pseudomonas aeruginosa. Clin Exp Immunol (1995) 1.26
Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun (1994) 1.23
Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori. Clin Diagn Lab Immunol (1995) 1.22
A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology (1994) 1.20
Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Infect Immun (1988) 1.17
Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun (1994) 1.07
Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J Clin Microbiol (2005) 1.04
Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4. Infect Immun (1993) 1.04
Population transcript accumulation of Pseudomonas aeruginosa exotoxin A and elastase in sputa from patients with cystic fibrosis. Infect Immun (1992) 1.04
Positive correlation of algD transcription to lasB and lasA transcription by populations of Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. Infect Immun (1997) 1.02
Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax (2006) 1.01
Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med Microbiol Immunol (2009) 0.94
The protease-antiprotease battle in the cystic fibrosis lung. J R Soc Med (1999) 0.90
Burkholderia vaccines: are we moving forward? Front Cell Infect Microbiol (2013) 0.90
Pseudomonas serology: confusion, controversy, and challenges. Thorax (2006) 0.86
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. J Cyst Fibros (2012) 0.84
Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA). Diagn Pathol (2014) 0.81
Effects of mucoid and non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients on inflammatory mediator release from human polymorphonuclear granulocytes and rat mast cells. Immunology (1992) 0.81
Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis. J Clin Microbiol (2009) 0.80
Association between transcript levels of the Pseudomonas aeruginosa regA, regB, and toxA genes in sputa of cystic fibrosis patients. Infect Immun (1994) 0.80
Histamine release from basophils in cystic fibrosis. Clin Exp Immunol (1989) 0.76
[Significance of Pseudomonas aeruginosa virulence factors for acute and chronic Pseudomonas aeruginosa infections]. Infection (1987) 0.75
Cystic fibrosis. Am Rev Respir Dis (1976) 6.62
Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun (1980) 6.61
Antiphagocytic Effect of Slime from a Mucoid Strain of Pseudomonas aeruginosa. Infect Immun (1971) 4.18
Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med (1979) 3.54
A new polysaccharide resembling alginic acid isolated from pseudomonads. J Biol Chem (1966) 3.43
Bacterial precipitins in serum of patients with cystic fibrosis. Lancet (1968) 3.29
Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains. J Infect Dis (1980) 3.29
Serogroups of Pseudomonas aeruginosa and the immune response of patients with cystic fibrosis. J Infect Dis (1970) 3.22
Incidence of mucoid Pseudomonas aeruginosa from clinical sources. Appl Microbiol (1969) 3.04
Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun (1982) 2.76
Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. J Infect Dis (1978) 2.60
Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis (1977) 2.50
Pseudomonas colonization in cystic fibrosis. A study of 160 patients. JAMA (1978) 2.42
Pseudomonas aeruginosa: immune status in patients with cystic fibrosis. Infect Immun (1972) 1.99
In vivo studies on protease and elastase from Pseudomonas aeruginosa. Jpn J Exp Med (1975) 1.87
Microscopic characterization of rabbit lung damage produced by Pseudomonas aeruginosa proteases. Infect Immun (1979) 1.75
Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections. J Pediatr (1971) 1.75
Influence of mucoidy on antibody coating of Pseudomonas aeruginosa. J Infect Dis (1979) 1.67
[Extracellular toxins of Pseudomonas aeruginosa. II. Effect of two proteases on human immunoglobulins IgG, IgA and secretory IgA (author's transl)]. Zentralbl Bakteriol A (1981) 1.62
Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis (1983) 1.56
Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs. Infect Immun (1981) 1.49
The penetration of antibiotics through sodium alginate and through the exopolysaccharide of a mucoid strain of Pseudomonas aeruginosa. Lancet (1981) 1.47
Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med (1980) 1.40
Immune complexes in the sputum of patients with cystic fibrosis suffering from chronic Pseudomonas aeruginosa lung infection. Acta Pathol Microbiol Scand C (1978) 1.00
Extracellular toxins of Pseudomonas aeruginosa. IV. Radioimmunoassay for detection of elastase. Zentralbl Bakteriol Mikrobiol Hyg A (1982) 0.95
Extracellular toxins of Pseudomonas aeruginosa. III. Radioimmunoassay for detection of alkaline protease. Zentralbl Bakteriol Mikrobiol Hyg A (1982) 0.89
Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis. Scand J Infect Dis (1979) 0.86
Phagocytosis of Pseudomonas aeruginosa by polymorphonuclear leukocytes and monocytes: effect of cystic fibrosis serum. Infect Immun (1982) 0.84
Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J Clin Microbiol (1993) 4.36
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet (1991) 3.37
Pathogenesis of cystic fibrosis. Lancet (1993) 3.34
Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J (2005) 3.30
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet (1991) 3.26
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol (1997) 3.23
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J (2000) 3.14
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand (1983) 3.13
Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (1999) 3.03
Anaerobic conditions induce expression of polysaccharide intercellular adhesin in Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun (2001) 2.72
Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol (1996) 2.55
N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (2001) 2.51
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet (2001) 2.51
Direct quantitative transcript analysis of the agr regulon of Staphylococcus aureus during human infection in comparison to the expression profile in vitro. Infect Immun (2000) 2.50
An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother (1986) 2.43
PCR and blood culture for detection of Escherichia coli bacteremia in rats. J Clin Microbiol (1999) 2.28
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother (1991) 2.09
Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother (1990) 2.08
Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa. J Clin Microbiol (1989) 2.07
Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand (1981) 2.03
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother (1987) 2.00
Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax (1992) 1.97
Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother (2004) 1.96
Cross-reactions between Legionella pneumophila (serogroup 1) and twenty-eight other bacterial species, including other members of the family Legionellaceae. Infect Immun (1983) 1.93
[Guidelines on antibiotics in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.93
Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre. Acta Pathol Microbiol Scand B (1980) 1.90
Crossed immunoelectrophoretic analysis of Legionella pneumophila serogroup 1 antigens. Infect Immun (1983) 1.89
Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J Antimicrob Chemother (2000) 1.85
Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis (1986) 1.85
Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol (2000) 1.85
Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun (1990) 1.81
An antigen common to a wide range of bacteria. I. The isolation of a 'common antigen' from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.75
Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiol Infect (1989) 1.69
Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulator agr, and bacterial growth phase. Infect Immun (2000) 1.68
The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol (1986) 1.67
Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology (2000) 1.66
[Extracellular toxins of Pseudomonas aeruginosa. II. Effect of two proteases on human immunoglobulins IgG, IgA and secretory IgA (author's transl)]. Zentralbl Bakteriol A (1981) 1.62
[Results of a representative survey of family planning behavior in West Germany 1985]. Geburtshilfe Frauenheilkd (1986) 1.62
Immunological cross-reaction between antigen Tp-4 of Treponema pallidum and an antigen common to a wide range of bacteria. Acta Pathol Microbiol Immunol Scand B (1984) 1.60
Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis (1983) 1.56
Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol (1999) 1.54
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun (1990) 1.51
Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol (1993) 1.51
Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol (1988) 1.50
Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol (1987) 1.49
Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinable Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol (1988) 1.46
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros (2008) 1.46
An antigen common to a wide range of bacteria. 2. A biochemical study of a "common antigen" from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.45
Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest (1989) 1.44
Sepsis in a newborn due to Pseudomonas aeruginosa from a contaminated tub bath. N Engl J Med (2001) 1.43
Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol (1994) 1.43
Properties of the photoactive chlorophyll-aII in photosynthesis. Z Naturforsch B (1969) 1.43
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother (1987) 1.42
Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax (1992) 1.42
Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros (2009) 1.41
Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun (1985) 1.41
A ten year review of colomycin. Respir Med (2000) 1.40
[Guidelines for antibiotic use in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.39
Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology (2001) 1.39
Regulation of Staphylococcus aureus capsular polysaccharide type 5: CO2 inhibition in vitro and in vivo. J Infect Dis (1997) 1.38
Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros (2002) 1.38
Innate immunity in cystic fibrosis lung disease. J Cyst Fibros (2012) 1.38
[Decreasing vaccination rate--increasing risk of epidemics]. Ugeskr Laeger (1996) 1.38
Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect Immun (1984) 1.37
Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro. Infect Immun (1984) 1.34
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS (2000) 1.33
Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis. Infect Immun (1983) 1.33
Relevance of host-derived and bacterial factors in Pseudomonas aeruginosa corneal infections. Invest Ophthalmol Vis Sci (1987) 1.32
Terminal truncations in amp C beta-lactamase from a clinical isolate of Pseudomonas aeruginosa. Eur J Biochem (1999) 1.30
Rhamnolipid of Pseudomonas aeruginosa in sputum of cystic fibrosis patients. Lancet (1987) 1.29
[Treatment of upper respiratory tract infections?]. Ugeskr Laeger (2000) 1.29
Production of N-acyl-L-homoserine lactones by P. aeruginosa isolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiol Lett (2000) 1.28
Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros (2011) 1.28
Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (1989) 1.28
Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect (2009) 1.27
Polyagglutinability due to loss of O-antigenic determinants in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand B (1985) 1.25
Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand (1987) 1.24
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother (2001) 1.24
Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol (1998) 1.22
Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori. Clin Diagn Lab Immunol (1995) 1.22
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS (1994) 1.22
Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol (1999) 1.22
Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol (1998) 1.21
Iron release from transferrin by pyoverdin and elastase from Pseudomonas aeruginosa. Infect Immun (1994) 1.21
Studies on hypersensitivity to bacterial antigens in intrinsic asthma. Allergy (1982) 1.20
Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol (1989) 1.20
Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs (2001) 1.19
Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob Agents Chemother (1997) 1.19
Diagnosis and treatment of cystic fibrosis. Respiration (2000) 1.19
Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS (1993) 1.19
Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS (1997) 1.19
Hypergammaglobulinemic purpura in cystic fibrosis. Acta Paediatr Scand (1978) 1.18